Potent Oral Antifungal Granted QIDP Status for Valley Fever

Spores of the fungal pathogen Coccidioides live in the soil and infect an estimated 150,000 people annually
Spores of the fungal pathogen Coccidioides live in the soil and infect an estimated 150,000 people annually

The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 (Viamet) for the treatment of coccidioidomycosis, or Valley Fever.

Valley Fever is an invasive fungal infection heavily concentrated in the Southwestern United States. Spores of the fungal pathogen Coccidioides live in the soil and infect an estimated 150,000 people annually. While the majority of cases are either self-limited or resolve with current treatments, about 5–10% of patients will develop a debilitating and fatal form of the disease often associated with chronic lung infection and dissemination to other body parts. 

Related Articles

VT-1598 is an oral, selective inhibitor of fungal CYP51. It has demonstrated highly potent activity against a broad range of fungal pathogens, including molds, yeasts and endemic fungi (Coccidioides, Histoplasma and Blastomyces species).

For more information visit Viamet.com.

Loading links....